REGIMMUNE-LIMITED
REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announced that the Phase 2b clinical data from 49 patients receiving RGI-2001 for the prevention of acute graft-versus-host disease (aGVHD) will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana on December 12, 2022.
This is an open label, single-arm Phase 2 study, evaluating the safety and efficacy of RGI-2001 for the prevention of aGVHD in subjects following allogeneic hematopoietic stem cell transplantation (HSCT). This study tests the hypothesis that RGI-2001 prevents GVHD by expanding regulatory T cells soon after allogeneic HSCT. The incidence and severity of aGVHD was evaluated in patients treated with RGI-2001 in addition to standard GVHD prevention medications. “Based on the analysis, RGI-2001 showed reduced incidence of aGVHD with an excellent safety profile. I am thrilled that the RGI-2001 study results have been selected for oral presentation at the ASH meeting. We look forward to sharing future findings as we work to deliver breakthrough immune medicines by harnessing the power of regulatory T cells,” said Kenzo Kosuda, CEO at REGiMMUNE Limited.
Session Name: Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Novel Therapies for Graft-versus-Host Disease
Session Date and Time: Monday, December 12, 2022, 10:30 - 12:00 p.m. CT
Presentation time: 11:45 a.m. CT
Location: Ernest N. Morial Convention Center, 252-254 and online
Presenter: Yi-Bin Chen, MD
Publication Number: 774
Title: RGI-2001 Infusion for Prevention of Acute GVHD after Allogeneic Hematopoietic Cell Transplantation
Submission ID: 162512
About RGI-2001
RGI-2001 is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. Alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant natural killer T cells (iNKT). Liposomal alpha-GalCer promotes tolerogenic immune cascades, resulting in the activation and expansion of regulatory T cells (Tregs). RGI-2001 is REGiMMUNE’s lead drug candidate currently in Phase 3 planning for the prophylaxis of acute graft-versus-host disease (aGVHD).
About REGiMMUNE Limited
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). REGiMMUNE is creating a pipeline of novel product candidates that either enhance Treg activities for immune diseases or suppress Treg activities for cancer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221106005119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deepfakes Already Hitting Businesses as Often as Traditional Fraud, Regula Survey Finds17.9.2025 08:00:00 CEST | Press release
Fresh survey data from Regula, a global developer of identity verification (IDV) solutions and forensic devices, shows that the line between traditional fraud and impersonation attacks has vanished. Identity spoofing, biometric fraud, and AI-powered deepfakes have already struck one in three organizations worldwide, catching up with long-standing fraud tactics like forged documents and social engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916314726/en/ Regula’s survey shows that impersonation attacks overtake traditional fraud schemes. Three impersonation-driven tactics now dominate the fraud playbook, each exploiting weaknesses in verification: Identity spoofing (reported by 34% of organizations) — Holding up a printed photo, replaying a video, or showing a screen image to a camera. Often used to mass-open accounts for scams or mule networks. Biometric fraud (34%) — Physical deceptions like fake fingerprints
Overture Life Launches European Preorder Waitlist for DaVitri, the World’s First Microfluidics-Based Automated Vitrification Platform17.9.2025 07:00:00 CEST | Press release
Ahead of receipt of anticipated CE Mark, European customers can begin requesting DaVitri to expand patient access to high-quality IVF Overture Life, the innovator modernizing IVF to optimize reproductive freedom, today announced the launch of its European preorder waitlist for DaVitri, the world’s first automated vitrification platform. The waitlist ensures in vitro fertilization (IVF) facilities will be among the first in Europe to harness DaVitri to reduce manual workloads for their embryologists while eliminating operator variability, thereby providing patients with faster, more consistent procedures. As infertility rates spike worldwide, interest in egg freezing continues to rise while the infrastructure to support it lags behind. Egg freezing requires vitrification, typically a time-intensive, manual process vulnerable to human error that can only be performed by extensively trained embryologists. This has resulted in variability in egg and embryo survival rates that directly impa
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 07:00:00 CEST | Press release
Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe hidradenitis suppurativa (HS) through Week 24At Week 24, nearly 60% of efficacy-evaluable patients among both povorcitinib treatment groups achieved HiSCR50Additionally, patients treated with povorcitinib achieved HiSCR75 (31.0%-40.3%), HiSCR90 (13.8%-27.7%) and HiSCR100 (9.2%-21.3%) through Week 24Povorcitinib-treated patients also achieved greater improvements in skin pain by the first visit (Week 3) through Week 24 with 62%-70% achieving mild or no pain at Week 24 Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin17.9.2025 07:00:00 CEST | Press release
Results from a real-world clinical study conducted in China, to be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress, reveal that modern lifestyles and environmental triggers significantly impact individuals with sensitive skin1 Data show that people with sensitive skin living in modern environments have higher levels of inflammation compared to those living traditional, less stressful lifestyles1 This first-of-its-kind study was conducted by Galderma’s Global Sensitive Skincare Faculty (GSSF) as part of the company’s commitment to transforming the understanding and care of sensitive skin1 Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (GSSF), will be pres
Ant International Recognized as an Inaugural Foreign Institution Partner by China’s Cross-Border Interconnection Payment Gateway17.9.2025 06:24:00 CEST | Press release
Expanded direct connection enables Alipay+ to help global wallets build China merchant networkAnt is the largest player in the CPG scheme in terms of coverage, use cases and business volume Ant International is appointed as an inaugural foreign Institution Partner (FIP) of China’s Cross-border Interconnection Payment Gateway (CPG), under the guidance of the People’s Bank of China and the Payment & Clearing Association of China (PCAC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916704996/en/ Eric Jing, Chairman of Ant Group and Ant International, and Cyril Han, CEO of Ant Group, celebrating China's Top International consumer destinations with card and wallet partners. Ant International and Alipay are the largest player in the CPG scheme with the largest number of card network and wallet partners, the broadest use cases and largest business volume. The new CPG scheme is designed to raise connection efficiency and improv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom